Page last updated: 2024-12-06

hygromycin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID23777801
CHEMBL ID4647156
MeSH IDM0010798

Synonyms (20)

Synonym
SMP1_000163
hygromycin b ,
31282-04-9
hygromycin b from streptomyces hygroscopicus, lyophilized powder
hygromycin b from streptomyces hygroscopicus, powder, bioreagent, suitable for cell culture, suitable for insect cell culture
BCBCMAP01_000235
c20h37n3o13
AC-32610
GS-5543
(2s,3'r,3as,4s,4's,5'r,6r,6'r,7s,7as)-4-{[(1r,2s,3r,5s,6r)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy}-6'-[(1r)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)-tetrahydro-3ah-spiro[[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol
hygromycin b, from streptomyces hygroscopicus
hygromycin b from streptomyces hygroscopicus, plant cell culture tested, bioreagent, >=60% (hplc), lyophilized powder
hygromycin b from streptomyces hygroscopicus, vetec(tm) reagent grade
AKOS032949592
o-6-amino-6-deoxy-l-glycero-d-galacto-heptopyranosylidene-(1-2-3)-o-beta-d-talopyranosyl(1-5)-2-deoxy-n3-methyl-d-streptamine
HB4420
(2s,3r,3a's,4s,4's,5r,6r,6'r,7's,7a's)-4'-(((1r,2s,3r,5s,6r)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl)oxy)-6-((r)-1-amino-2-hydroxyethyl)-6'-(hydroxymethyl)octahydro-4'h-spiro[pyran-2,2'-[1,3]dioxolo[4,5-c]pyran]-3,4,5,7'-tetraol
1217468-11-5
H10464
CHEMBL4647156

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The induction increases with increasing dosage of the suppressor and decreases in the presence of an antisuppressor."( Nonrecombinant meiosis I nondisjunction in Saccharomyces cerevisiae induced by tRNA ochre suppressors.
Haber, JE; Louis, EJ, 1989
)
0.28
"Aminoglycoside antibiotics are indispensable for treatment of serious bacterial infections, and despite careful attention to dosage regimens, nephrotoxicity and ototoxicity still cause concern."( Expression of hygR in transgenic mice causes resistance to toxic effects of hygromycin B in vivo.
Aubrecht, J; Goad, ME; Schiestl, RH; Simpson, EM, 1997
)
0.3
" We performed dose-response analyses with 23 steroids in 96-well plate format."( Novel stably transfected human reporter cell line AIZ-AR as a tool for an assessment of human androgen receptor transcriptional activity.
Bartonkova, I; Dvorak, Z; Novotna, A, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1690369Antifungal activity against Ustilago maydis AB33 assessed as diameter of zone inhibition at 50 ug by Kirby-Bauer disk diffusion method2020European journal of medicinal chemistry, Apr-01, Volume: 191Cladosins L-O, new hybrid polyketides from the endophytic fungus Cladosporium sphaerospermum WBS017.
AID1690370Antifungal activity against Saccharomyces cerevisiae ESM356-1 assessed as diameter of zone inhibition at 50 ug by Kirby-Bauer disk diffusion method2020European journal of medicinal chemistry, Apr-01, Volume: 191Cladosins L-O, new hybrid polyketides from the endophytic fungus Cladosporium sphaerospermum WBS017.
AID1668117Fungicidal activity against hyphae form of Candida albicans ATCC 24433 assessed as reduction in bacterial viability at 474 uM measured after 6 hrs by time kill assay2020Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
Antifungal polyketide derivatives from the endophytic fungus Aplosporella javeedii.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (841)

TimeframeStudies, This Drug (%)All Drugs %
pre-199085 (10.11)18.7374
1990's270 (32.10)18.2507
2000's276 (32.82)29.6817
2010's180 (21.40)24.3611
2020's30 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (1.16%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other849 (98.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]